Lung Foundation Australia supports all aspects of lung health from asthma and COPD to pulmonary hypertension and cancer, providing community education and a toll-free patient information and support centre.
The organisation also supports research, develops educational fact-sheets, trains health professionals, and undertakes community awareness activity and advocacy around Australia.
In 2018, GSK supported a range of activities for the Lung Foundation Australia including:
- Expanding the Lungs in action program for patients with chronic lung disease ($59,900) - a program based around the evidence-based intervention of pulmonary maintenance exercise. The program provides people with chronic lung disease, the essential need to maintain the gains achieved in pulmonary rehabilitation.
- Providing financial support ($15,000) for patient information and support to provide up-to-date information and education to people impacted by pulmonary arterial hypertension (PAH).
Additionally, in 2018 GSK donated 3,000 Ellipta, 3,000 Accuhaler and 3,000 MDI placebo inhaler devices at an approximate cost of $40,350.